Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters
- PMID: 15728203
- DOI: 10.1210/jc.2004-2279
Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters
Abstract
In hyperandrogenic women, several phenotypes may be observed. This includes women with classic polycystic ovary syndrome (C-PCOS), those with ovulatory (OV) PCOS, and women with idiopathic hyperandrogenism (IHA), which occurs in women with normal ovaries. Where other causes have been excluded, we categorized 290 hyperandrogenic women who were seen consecutively for this complaint between 1993 and 2004 into these three subgroups. The aim was to compare the prevalence of obesity, insulin resistance, and dyslipidemia as well as increases in C-reactive protein and homocysteine in these different phenotypes with age-matched ovulatory controls of normal weight (n = 85) and others matched for body mass index (BMI) with women with C-PCOS (n = 42). Although BMI affected fasting serum insulin and the Quantitative Insulin-Sensitivity Check Index, these markers of insulin resistance were greatest in C-PCOS (n = 204), followed by OV-PCOS (n = 50) and then IHA (n = 33). Androgen levels were similar in OV-PCOS and IHA but were higher in C-PCOS, whereas gonadotropins were similar in all groups. Lipid abnormalities were highest in C-PCOS and OV-PCOS and were normal in IHA. C-reactive protein was elevated in C-PCOS and OV-PCOS but not IHA. Homocysteine was elevated only in C-PCOS. Overall, the prevalence of obesity (BMI > 30) was 29% in C-PCOS, 8% in OV-PCOS, and 15% in IHA and insulin resistance (Quantitative Insulin-Sensitivity Check Index < 0.33) was 68% in C-PCOS, 36% in OV-PCOS, and 26% in IHA. The prevalence of having at least one elevated cardiovascular risk marker was 45% in C-PCOS 38% in OV-PCOS and was not increased on IHA (6%). These results suggest that among hyperandrogenic women the prevalence of abnormal metabolic and cardiovascular risk parameters is greatest in C-PCOS, followed by OV-PCOS and then women with IHA. Moreover, in that in OV-PCOS and IHA, ages and weights were similar yet the prevalence of metabolic and cardiovascular risk was greater in OV-PCOS, the finding of polycystic ovaries may be a significant modifying factor.
Similar articles
-
Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes.J Endocrinol Invest. 2007 Feb;30(2):111-6. doi: 10.1007/BF03347408. J Endocrinol Invest. 2007. PMID: 17392600
-
Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.J Clin Endocrinol Metab. 2000 Mar;85(3):995-1000. doi: 10.1210/jcem.85.3.6452. J Clin Endocrinol Metab. 2000. PMID: 10720029 Clinical Trial.
-
Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.Hum Reprod. 2013 Aug;28(8):2245-52. doi: 10.1093/humrep/det119. Epub 2013 Apr 17. Hum Reprod. 2013. PMID: 23595974
-
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.Hum Reprod Update. 2009 Jul-Aug;15(4):477-88. doi: 10.1093/humupd/dmp008. Epub 2009 Mar 11. Hum Reprod Update. 2009. PMID: 19279045 Review.
-
Mild androgen phenotypes.Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):207-20. doi: 10.1016/j.beem.2006.02.001. Best Pract Res Clin Endocrinol Metab. 2006. PMID: 16772152 Review.
Cited by
-
Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort.CJC Open. 2023 Dec 16;6(2Part B):314-326. doi: 10.1016/j.cjco.2023.12.010. eCollection 2024 Feb. CJC Open. 2023. PMID: 38487056 Free PMC article.
-
Western-style diet in the presence of elevated circulating testosterone induces adipocyte hypertrophy without proinflammatory responses in rhesus macaques.Am J Reprod Immunol. 2023 Oct;90(4):e13773. doi: 10.1111/aji.13773. Am J Reprod Immunol. 2023. PMID: 37766405
-
Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs.J Clin Med. 2023 Sep 12;12(18):5921. doi: 10.3390/jcm12185921. J Clin Med. 2023. PMID: 37762862 Free PMC article.
-
N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS).J Ovarian Res. 2023 Apr 12;16(1):73. doi: 10.1186/s13048-023-01147-9. J Ovarian Res. 2023. PMID: 37046273 Free PMC article.
-
Diagnostic Performance of Ovarian Morphology on Ultrasonography across Anovulatory Conditions-Impact of Body Mass Index.Diagnostics (Basel). 2023 Jan 19;13(3):374. doi: 10.3390/diagnostics13030374. Diagnostics (Basel). 2023. PMID: 36766481 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials